Actively Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Led by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Updated on 2026-04-23
230
Participants Needed
13
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
CONDITIONS
Official Title
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy greater than 3 months
- Histologically or cytologically confirmed advanced solid tumors including head and neck squamous cell carcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, hormone receptor-positive and HER2-negative breast carcinoma with prior CDK4/6 inhibitor treatment, platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers, or triple negative breast cancer
- Disease must be advanced, recurrent, or metastatic following standard of care treatments
- Adequate blood, liver, and kidney function
- Presence of tumor lesions or metastases suitable for biopsy, excluding bone metastases
You will not qualify if you...
- Active and clinically significant infection
- Refractory nausea or vomiting, chronic gastrointestinal disease, or prior significant bowel surgery causing absorption issues for GTAEXS617
- Symptomatic central nervous system malignancy or metastases
- Concurrent active or previous malignancy
- Prior organ or allogeneic stem-cell transplantation
- Moderate or severe cardiovascular disease
- Received anticancer therapy within 28 days or 5 half-lives before first dose
- Received strong/moderate CYP3A inhibitors or inducers within 14 days or 5 half-lives before first dose
- Received inhibitors or inducers of P-glycoprotein or breast cancer resistance protein within 14 days or 5 half-lives before first dose
- Received substrates of organic anion transporting peptide or breast cancer resistance protein within 14 days or 5 half-lives before first dose
- Unresolved or unstable serious toxic side effects from prior chemotherapy or radiotherapy
- Major surgery less than 28 days before first dose
- Other protocol-specific inclusion or exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90089
Actively Recruiting
2
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
START San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
4
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
5
GZA Ziekenhuizen - Campus Sint-Augustinus
Antwerp, Belgium
Actively Recruiting
6
Clinique Universitaires Saint-Luc
Brussels, Belgium
Actively Recruiting
7
Institute Jules Bordet
Brussels, Belgium
Actively Recruiting
8
CHU Sart Tilman
Liège, Belgium
Actively Recruiting
9
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Actively Recruiting
10
UCL Hospitals NHS Foundation Trust
London, United Kingdom
Actively Recruiting
11
The Christie NHS Foundation Trust
Manchester, United Kingdom
Actively Recruiting
12
Newcastle Upon Tyne NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Actively Recruiting
13
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Actively Recruiting
Research Team
E
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here